

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

Immune Tolerance Network (ITN)

RRID:SCR_001535

Type: Tool

Proper Citation

Immune Tolerance Network (ITN) (RRID:SCR_001535)

Resource Information

URL: <http://www.immunetolerance.org/>

Proper Citation: Immune Tolerance Network (ITN) (RRID:SCR_001535)

Description: International clinical research consortium dedicated to the clinical evaluation of novel tolerogenic approaches for the treatment of autoimmune diseases, asthma and allergic diseases, and the prevention of graft rejection. They aim to advance the clinical application of immune tolerance by performing high quality clinical trials of emerging therapeutics integrated with mechanism-based research. In particular, they aim to: * Establish new tolerance therapeutics * Develop a better understanding of the mechanisms of immune function and disease pathogenesis * Identify new biomarkers of tolerance and disease Their goals are to identify and develop treatment game changers for tolerance modulating therapies for the treatment of immune mediated diseases and disabling conditions, and to conduct high quality, innovative clinical trials and mechanistic studies not likely to be funded by other sources or to be conducted by private industry that advance our understanding of immunological disorders. In the Immune Tolerance Network's (ITN) unique hybrid academic/industry model, the areas of academia, government and industry are integral to planning and conducting clinical studies. They develop and fund clinical trials and mechanistic studies in partnership. Their development model is a unique, interactive process. It capitalizes on their wide-ranging, multidisciplinary expertise provided by an advisory board of highly respected faculty from institutions worldwide. This model gives investigators special insight into developing high quality research studies. The ITN is comprised of leading scientific and medical faculty from more than 50 institutions in nine countries worldwide and employs over 80 full-time staff at the University of California San Francisco (UCSF), Bethesda, Maryland and Benaroya Research Institute in Seattle, Washington.

Abbreviations: ITN

Resource Type: clinical trial, data or information resource, funding resource, portal, topical portal

Keywords: immune tolerance, prevent, cure, disease, multiple sclerosis, therapy, biomarker, transplant

Related Condition: Type 1 diabetes, Diabetes, Allergy, Asthma, Autoimmune disease, Transplantation, Immunological disorder

Funding: NIAID N01AI15416

Resource Name: Immune Tolerance Network (ITN)

Resource ID: SCR_001535

Alternate IDs: nlx_152838

Record Creation Time: 20220129T080208+0000

Record Last Update: 20260905T132435+0000

Ratings and Alerts

No rating or validation information has been found for Immune Tolerance Network (ITN).

No alerts have been found for Immune Tolerance Network (ITN).

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Mexhitaj I, et al. (2022) Stabilization of leukocytes from cerebrospinal fluid for central immunophenotypic evaluation in multicenter clinical trials. Journal of immunological methods, 510, 113344.

Docampo MJ, et al. (2021) Mechanistic and Biomarker Studies to Demonstrate Immune Tolerance in Multiple Sclerosis. Frontiers in immunology, 12, 787498.

Roostaei T, et al. (2021) Proximal and distal effects of genetic susceptibility to multiple sclerosis on the T cell epigenome. Nature communications, 12(1), 7078.

Huffaker MF, et al. (2021) Approaches to Establishing Tolerance in Immune Mediated Diseases. Frontiers in immunology, 12, 744804.

Mrad MF, et al. (2017) Effect of vitamin D replacement on immunological biomarkers in patients with multiple sclerosis. Clinical immunology (Orlando, Fla.), 181, 9.

Kivis??kk P, et al. (2014) Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis. PloS one, 9(7), e103716.

Herold KC, et al. (2013) Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes, 62(11), 3766.

Brooks-Worrell B, et al. (2013) Prevention versus intervention of type 1 diabetes. Clinical immunology (Orlando, Fla.), 149(3), 332.

Vargas-Lowy D, et al. (2013) Increased Th17 response to myelin peptides in pediatric MS. Clinical immunology (Orlando, Fla.), 146(3), 176.

Skyler JS, et al. (2011) Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes, 60(1), 1.

Luo X, et al. (2010) Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity, 32(4), 488.

Germain RN, et al. (2010) Vaccines and the future of human immunology. Immunity, 33(4), 441.

Rewers M, et al. (2009) Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabetes care, 32(10), 1769.

Davis MM, et al. (2008) A prescription for human immunology. Immunity, 29(6), 835.

Mallone R, et al. (2004) MHC Class II tetramers and the pursuit of antigen-specific T cells: define, deviate, delete. Clinical immunology (Orlando, Fla.), 110(3), 232.